NASDAQ:INAB IN8bio (INAB) Stock Price, News & Analysis $0.13 0.00 (-3.08%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.13 +0.00 (+0.79%) As of 05/21/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About IN8bio Stock (NASDAQ:INAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IN8bio alerts:Sign Up Key Stats Today's Range$0.12▼$0.1350-Day Range$0.13▼$0.2452-Week Range$0.11▼$1.74Volume1.30 million shsAverage Volume1.98 million shsMarket Capitalization$11.44 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company OverviewIN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.Read More… IN8bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreINAB MarketRank™: IN8bio scored higher than 64% of companies evaluated by MarketBeat, and ranked 368th out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingIN8bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIN8bio has only been the subject of 1 research reports in the past 90 days.Read more about IN8bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for IN8bio are expected to grow in the coming year, from ($0.56) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IN8bio is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IN8bio is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIN8bio has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.59% of the float of IN8bio has been sold short.Short Interest Ratio / Days to CoverIN8bio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IN8bio has recently decreased by 10.87%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIN8bio does not currently pay a dividend.Dividend GrowthIN8bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.59% of the float of IN8bio has been sold short.Short Interest Ratio / Days to CoverIN8bio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IN8bio has recently decreased by 10.87%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News SentimentN/A News SentimentIN8bio has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.Search Interest14 people have searched for INAB on MarketBeat in the last 30 days. This is an increase of 367% compared to the previous 30 days.MarketBeat Follows3 people have added IN8bio to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, IN8bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of IN8bio is held by insiders.Percentage Held by Institutions92.05% of the stock of IN8bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IN8bio's insider trading history. Receive INAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter. Email Address INAB Stock News HeadlinesIN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025May 14, 2025 | globenewswire.comHC Wainwright Issues Negative Estimate for IN8bio EarningsMay 13, 2025 | americanbankingnews.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.May 22, 2025 | Porter & Company (Ad)IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical ProductsMay 12, 2025 | globenewswire.comIN8bio Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 7, 2025 | globenewswire.comIN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific ConferencesApril 29, 2025 | globenewswire.comIN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025April 28, 2025 | globenewswire.comIN8bio to Present New Preclinical Data on Novel Gamma-Delta (?d) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025March 31, 2025 | tmcnet.comSee More Headlines INAB Stock Analysis - Frequently Asked Questions How have INAB shares performed this year? IN8bio's stock was trading at $0.2572 at the start of the year. Since then, INAB stock has decreased by 51.0% and is now trading at $0.1260. View the best growth stocks for 2025 here. How were IN8bio's earnings last quarter? IN8bio, Inc. (NASDAQ:INAB) released its quarterly earnings data on Thursday, May, 8th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. When did IN8bio IPO? IN8bio (INAB) raised $44 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 4,000,000 shares at $10.00-$12.00 per share. B. Riley Securities served as the underwriter for the IPO. Who are IN8bio's major shareholders? IN8bio's top institutional investors include Alyeska Investment Group L.P. (2.29%), AIGH Capital Management LLC (1.78%) and Sigma Planning Corp (0.86%). Insiders that own company stock include William Tai-Wei Ho, Lawrence Lamb, Patrick Mccall, Kate Rochlin, Trishna Goswami and Jeremy R Graff. View institutional ownership trends. How do I buy shares of IN8bio? Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IN8bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that IN8bio investors own include NVIDIA (NVDA), Ford Motor (F), GitLab (GTLB), Cognition Therapeutics (CGTX), CrowdStrike (CRWD), Chevron (CVX) and Meta Platforms (META). Company Calendar Last Earnings5/08/2025Today5/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INAB CIK1740279 Webwww.in8bio.com Phone646-600-6438FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+4,661.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-197.15% Return on Assets-130.48% Debt Debt-to-Equity Ratio0.05 Current Ratio1.84 Quick Ratio1.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book0.22Miscellaneous Outstanding Shares90,772,000Free Float61,248,000Market Cap$11.44 million OptionableNot Optionable Beta0.23 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:INAB) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.